Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $8.0 million.

  • Stoke Therapeutics' Share-based Compensation rose 727.25% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.6 million, marking a year-over-year increase of 1183.04%. This contributed to the annual value of $27.5 million for FY2024, which is 869.57% up from last year.
  • Per Stoke Therapeutics' latest filing, its Share-based Compensation stood at $8.0 million for Q3 2025, which was up 727.25% from $7.6 million recorded in Q2 2025.
  • Stoke Therapeutics' Share-based Compensation's 5-year high stood at $8.0 million during Q3 2025, with a 5-year trough of $5.0 million in Q1 2022.
  • Over the past 4 years, Stoke Therapeutics' median Share-based Compensation value was $6.6 million (recorded in 2023), while the average stood at $6.5 million.
  • As far as peak fluctuations go, Stoke Therapeutics' Share-based Compensation crashed by 810.26% in 2024, and later skyrocketed by 2482.44% in 2025.
  • Stoke Therapeutics' Share-based Compensation (Quarter) stood at $5.8 million in 2022, then rose by 4.54% to $6.1 million in 2023, then increased by 17.51% to $7.2 million in 2024, then rose by 12.14% to $8.0 million in 2025.
  • Its Share-based Compensation stands at $8.0 million for Q3 2025, versus $7.6 million for Q2 2025 and $6.8 million for Q1 2025.